MaxCyte, Inc. (MXCT) Operating margin 2019–2025
MaxCyte, Inc. (MXCT) operating margin by fiscal year — reported operating income divided by reported revenue.
-247.6%FY2025 · since FY2019: -93.7% → -247.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -247.6% | -17.2 pp |
| FY2024 | -230.5% | +17.3 pp |
| FY2023 | -247.7% | -152.5 pp |
| FY2022 | -95.2% | -10.9 pp |
| FY2021 | -84.3% | -12.8 pp |
| FY2020 | -71.6% | +22.1 pp |
| FY2019 | -93.7% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More MXCT financial trends
MXCT RevenueMXCT Net incomeMXCT Net marginMXCT Gross profitMXCT Gross marginMXCT Operating incomeMXCT Operating cash flowMXCT Free cash flowMXCT Capital expendituresMXCT Return on equityMXCT Stock buybacksMXCT Dividends paidMXCT Total assetsMXCT Total liabilitiesMXCT Shareholders’ equityMXCT overview →